Login / Signup

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.

Thomas LundMichael Tveden GundesenAnnette Juul VangstedCarsten HellebergEinar HaukåsTrine SilkjærJon Thor AsmussenElena Manuela TeodorescuBo Amdi JensenTobias Schmidt SlørdahlHareth NahiAnders WaageNiels AbildgaardSchjesvold Fredriknull null
Published in: Blood cancer journal (2024)
Keyphrases
  • multiple myeloma
  • multiple sclerosis
  • bone mineral density
  • combination therapy
  • postmenopausal women
  • body composition
  • bone regeneration